Daan Gene

Guangzhou Daan Gene Co., Ltd. is a state-owned high-tech biomedical enterprise that focuses on molecular diagnostic technology and integrates the independent research and development, production, and sales of clinical testing reagents, instruments, and supporting consumables. As one of the first batch of in vitro diagnostic high-tech enterprises in China, the company was listed on the Shenzhen Stock Exchange in 2004 (stock code: SZ002030). After years of independent innovation breakthroughs and stable operation, Daan Gene has been selected as a National Intellectual Property Demonstration Enterprise multiple times, and its self-developed products have won titles such as "National Key New Product" and "Guangdong Province Key New Product."

After more than three decades of accumulation, Daan Gene has achieved full coverage of the PCR technology industry chain, including R&D and production, core raw materials, quality control products, instrument R&D and production, and testing services. The company's business scope covers many fields such as medical devices, medical and health services, elderly care, food safety, and industrial investment, all based on diagnostic technologies including molecular diagnostics, immunoassay, biochemical diagnostics, and POCT. With multiple product lines such as infectious diseases, eugenics and prenatal care, precision medicine, blood screening, public health, instruments and consumables, and scientific research services, the company has comprehensively laid out its position in the in vitro diagnostic industry, continuously extending its industrial layout into the broader health sector. As a high-tech enterprise, Daan Gene continuously overcomes "bottleneck" problems, achieving "self-production and self-manufacturing" of core raw materials, laying a solid foundation for capacity expansion.

At present, Daan Gene has achieved horizontal and vertical coverage of the full PCR industry chain, including R&D and production, core raw materials, quality control products, instrument R&D and production, and testing services, providing products and services to more than 140 countries and regions nationwide and worldwide. Guangzhou Daan Gene Co., Ltd. is a state-owned high-tech biomedical enterprise that focuses on molecular diagnostic technology and integrates the independent research and development, production, and sales of clinical testing reagents, instruments, and supporting consumables. As one of the first batch of in vitro diagnostic high-tech enterprises in China, the company was listed on the Shenzhen Stock Exchange in 2004 (stock code: SZ002030). After years of independent innovation breakthroughs and stable operation, Daan Gene has been selected as a National Intellectual Property Demonstration Enterprise multiple times, and its self-developed products have won titles such as "National Key New Product" and "Guangdong Province Key New Product."

After more than three decades of accumulation, Daan Gene has achieved full coverage of the PCR technology industry chain, including R&D and production, core raw materials, quality control products, instrument R&D and production, and testing services. The company's business scope covers many fields such as medical devices, medical and health services, elderly care, food safety, and industrial investment, all based on diagnostic technologies including molecular diagnostics, immunoassay, biochemical diagnostics, and POCT. With multiple product lines such as infectious diseases, eugenics and prenatal care, precision medicine, blood screening, public health, instruments and consumables, and scientific research services, the company has comprehensively laid out its position in the in vitro diagnostic industry, continuously extending its industrial layout into the broader health sector. As a high-tech enterprise, Daan Gene continuously overcomes "bottleneck" problems, achieving "self-production and self-manufacturing" of core raw materials, laying a solid foundation for capacity expansion.

At present, Daan Gene has achieved horizontal and vertical coverage of the full PCR industry chain, including R&D and production, core raw materials, quality control products, instrument R&D and production, and testing services, providing products and services to more than 140 countries and regions nationwide and worldwide.